Last updated at 03 Apr 2026 06:17 AM
Director
DIN: 01620938
Prasad Sivadas is currently associated with 2 companies in various capacities such as Managing Director and Director. They serve as a Director at INTEGRON PHARMA PRIVATE LIMITED and have other roles in different companies. They are registered with the Ministry of Corporate Affairs (MCA) of India and hold a DIN of 01620938.Prasad Sivadas has previously been associated with 1 company in roles such as Additional Director.Prasad Sivadas is currently involved in 2 different roles. Their most recent position is with INOTS MEDITECH PRIVATE LIMITED as a Director. The first company Prasad Sivadas was appointed to as a director was INTEGRON PHARMA PRIVATE LIMITED. Prasad Sivadas is not disqualified by the Registrar of Companies under Section 164(2), and their DIN has not been deactivated due to failure to file the DIR-3 KYC Form.
Prasad Sivadas is currently associated with 2 companies in various capacities such as Managing Director and Director. They serve as a Director at INTEGRON PHARMA PRIVATE LIMITED and have other roles in different companies. They are registered with the Ministry of Corporate Affairs (MCA) of India and hold a DIN of 01620938.Prasad Sivadas has previously been associated with 1 company in roles such as Additional Director.Prasad Sivadas is currently involved in 2 different roles. Their most recent position is with INOTS MEDITECH PRIVATE LIMITED as a Director. The first company Prasad Sivadas was appointed to as a director was INTEGRON PHARMA PRIVATE LIMITED. Prasad Sivadas is not disqualified by the Registrar of Companies under Section 164(2), and their DIN has not been deactivated due to failure to file the DIR-3 KYC Form.
2
Male
India
Gain instant access to verified contact details.
Current Companies (2)
Current LLPs (0)
Past Companies (1)
3y 1m 1y 7m Interval
| Company Name | Designation | Date of Appointment |
|---|---|---|
| INTEGRON PHARMA PRIVATE LIMITED | Managing Director | 07-Jan-2011 |
| INOTS MEDITECH PRIVATE LIMITED | Director | 02-Apr-2026 |